Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Xyphos Biosciences'...

    Xyphos Biosciences' ACCEL technology platform gets US patent

    Farhat NasimWritten by Farhat Nasim Published On 2019-04-20T09:15:11+05:30  |  Updated On 20 April 2019 9:15 AM IST
    Xyphos Biosciences ACCEL technology platform gets US patent

    California: Xyphos Biosciences Inc. recently announced the issuance of U.S. Patent No. 10,259,858, entitled “Insertable Variable Fragments of Antibodies and Modified Alpha 1-Alpha 2 Domains of NKG2D Ligands and Non-Natural NKG2D Ligands that Bind Non-Natural Receptors.”


    This patent, based on inventions by Xyphos scientists and issued to Xyphos, covers its ACCEL technology platform and includes broad composition-of-matter claims for its cell therapy products. Using this technology, company researchers are working toward programming a patient’s own immune cells to attack tumour cells with greater specificity and potentially lower toxicity compared to currently available cell therapies.


    Commenting on the issue, James Knighton, Chief Executive Officer of Xyphos said, “This powerful technology should enable us to address several key issues that have arisen in first generation cell therapies, such as cancer relapse, side effects, cell exhaustion and the inability to target solid tumours.”


    “We have an elegant, validated solution to targeting and controlling cells that does not require the engineering of complex intracellular machinery. Instead, our modular approach is easy to translate into treatments and capable of addressing multiple tumour targets, providing versatility and flexibility in order to successfully treat different cancers,” he added.


    Unlike the first generation of approved cell therapies and complicated intracellular engineering approaches, the ACCEL technology is designed to allow greater flexibility in targeting tumour cells and control of the activity of cell therapy products. In addition, the platform provides for the specific functional modulation of those products. Xyphos’ solution is readily modifiable for use with different therapeutic cell types and varied tumour targets.


    The ACCEL (Advanced Cellular Control through Engineered Ligands) platform enables precise control of activity and targeting of Xyphos’ universal CAR-T cell, termed convertibleCAR-T cell. Xyphos’ convertibleCAR technology exploits a powerful immune surveillance pathway involving NKG2D receptors that are naturally present on different cell types within the immune system including natural killer (NK) cells and some T-cells.


    Through protein engineering, Xyphos engineered the natural receptor to be inactive until “turned-on” by a proprietary bispecific antibody also engineered by Xyphos, called a MicAbody protein. Once the MicAbody protein is introduced, one end binds exclusively to the inactive receptors on the convertibleCAR-T cell while the other binds the target on the malignant cell, activating the convertibleCAR-T cell to aggressively destroy it.


    The resulting platform enables a single CAR-T cell to be precisely controlled and targeted to any specific antigen-expressing cell of choice using one or more tumour-specific MicAbody proteins. Using bispecific MIC-effector fusions (MicAdaptor™ proteins), Xyphos can externally deliver critical functionality (e.g. cytokine stimulation, checkpoint blockade, cell ablation, imaging agents, etc.) specifically to the Xyphos convertibleCAR-T cells.


    Also Read: Alchem solves stability dilemma for micronized DIGOXIN; files PATENT for novel production process

    AccelACCEL technology platformantibodiesantibodybiosciencesBiotechnology companycancerdrug patentModified Alpha 1-Alpha 2 DomainsNKG2D LigandsNon-Natural NKG2D LigandsNon-Natural ReceptorspatentxyphosXyphos Biosciences Inc

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok